Carlsmed develops AI-enabled personalized spine surgery solutions targeting the surgical spine fusion market. The company's core product, the aprevo platform, combines proprietary surgical planning software with artificial intelligence-driven algorithms to design custom vertebral interbody implants tailored to individual patient anatomy. This outcomes-based approach aims to enable surgeons to optimize implant selection and surgical planning for spine fusion procedures.
The aprevo platform comprises two integrated components: surgical planning software that leverages AI to analyze patient imaging and anatomy, and custom-manufactured interbody implants designed specifically for each patient's spinal geometry. The company operates as a commercial-stage enterprise, having been incorporated in 2018.
Carlsmed maintains a lean operational footprint with approximately 89 full-time employees and is headquartered in Carlsbad, California. The company trades on Nasdaq and operates within the health information services and surgical medical instruments sectors, positioning it at the intersection of healthcare technology and orthopedic device manufacturing.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-2.12 | $-2.12 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-25 | 0001193125-26-071551 | SEC ↗ |